Correlation Between Pasithea Therapeutics and NRx Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Pasithea Therapeutics and NRx Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Pasithea Therapeutics and NRx Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Pasithea Therapeutics Corp and NRx Pharmaceuticals, you can compare the effects of market volatilities on Pasithea Therapeutics and NRx Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Pasithea Therapeutics with a short position of NRx Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Pasithea Therapeutics and NRx Pharmaceuticals.

Diversification Opportunities for Pasithea Therapeutics and NRx Pharmaceuticals

0.04
  Correlation Coefficient

Significant diversification

The 3 months correlation between Pasithea and NRx is 0.04. Overlapping area represents the amount of risk that can be diversified away by holding Pasithea Therapeutics Corp and NRx Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on NRx Pharmaceuticals and Pasithea Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Pasithea Therapeutics Corp are associated (or correlated) with NRx Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of NRx Pharmaceuticals has no effect on the direction of Pasithea Therapeutics i.e., Pasithea Therapeutics and NRx Pharmaceuticals go up and down completely randomly.

Pair Corralation between Pasithea Therapeutics and NRx Pharmaceuticals

Given the investment horizon of 90 days Pasithea Therapeutics Corp is expected to under-perform the NRx Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Pasithea Therapeutics Corp is 1.5 times less risky than NRx Pharmaceuticals. The stock trades about -0.11 of its potential returns per unit of risk. The NRx Pharmaceuticals is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  6.28  in NRx Pharmaceuticals on September 18, 2024 and sell it today you would earn a total of  0.15  from holding NRx Pharmaceuticals or generate 2.39% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthInsignificant
Accuracy84.13%
ValuesDaily Returns

Pasithea Therapeutics Corp  vs.  NRx Pharmaceuticals

 Performance 
       Timeline  
Pasithea Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Pasithea Therapeutics Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite inconsistent performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long term up-swing for the company investors.
NRx Pharmaceuticals 

Risk-Adjusted Performance

5 of 100

 
Weak
 
Strong
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in NRx Pharmaceuticals are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. In spite of fairly inconsistent basic indicators, NRx Pharmaceuticals showed solid returns over the last few months and may actually be approaching a breakup point.

Pasithea Therapeutics and NRx Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Pasithea Therapeutics and NRx Pharmaceuticals

The main advantage of trading using opposite Pasithea Therapeutics and NRx Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Pasithea Therapeutics position performs unexpectedly, NRx Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in NRx Pharmaceuticals will offset losses from the drop in NRx Pharmaceuticals' long position.
The idea behind Pasithea Therapeutics Corp and NRx Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Complementary Tools

Bonds Directory
Find actively traded corporate debentures issued by US companies
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation